Korea, Republic of (KR)

Long-lifetime spin excitations near domain walls in 1T-TaS2 (2022) Aishwarya A, Raghavan A, Howard S, Cai Z, Thakur GS, Won C, Cheong SW, et al. Journal article Nested sampling for physical scientists (2022) Ashton G, Bernstein N, Buchner J, Chen X, Csányi G, Fowlie A, Feroz F, et al. Journal article, Review article Breast cancer risks associated with missense variants in breast cancer susceptibility genes (2022) Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, Gonzalez-Neira A, Heijl SM, et al. Journal article Characteristics of ALD-ZnO Thin Film Transistor Using H2O and H2O2 as Oxygen Sources (2022) Yang J, Bahrami A, Ding X, Lehmann S, Kruse N, He S, Wang B, et al. Journal article Electronic Structures of Group III–V Element Haeckelite Compounds: A Novel Family of Semiconductors, Dirac Semimetals, and Topological Insulators (2022) Khazaei M, Ranjbar A, Kang YG, Liang Y, Khaledialidusti R, Bae S, Raebiger H, et al. Journal article Partitioning RNAs by length improves transcriptome reconstruction from short-read RNA-seq data (2022) Ringeling FR, Chakraborty S, Vissers C, Reiman D, Patel AM, Lee KH, Hong A, et al. Journal article Physiological and Clinical Aspects of Bioactive Peptides from Marine Animals (2022) Chakniramol S, Wierschem A, Cho MG, Bashir KMI Journal article, Review article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis (2022) Balmana J, Fasching P, Delaloge S, Park YH, Eisen A, Bourgeois H, Kemp Z, et al. Conference contribution Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) (2022) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer (2022) Mcarthur H, Cortes J, Dent R, Pusztai L, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution